Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021311 | 0.84 | TRPM8 (0.47) | METAP1TDP1KDM4EFFAR1L3MBTL1 | |
| SCHEMBL4017115 | 0.82 | GPR39 (0.41) | METAP1TDP1KDM4EFFAR1GRM5 | |
| SCHEMBL4024276 | 0.82 | KDM4E (0.50) | TDP1KDM4EFFAR1CCR1CCR5 | |
| SCHEMBL2836367 | 0.81 | ACLY (0.39) | METAP1FFAR1GRM5 | |
| SCHEMBL4017695 | 0.80 | CYP1A2 (0.43) | METAP1KDM4EFFAR1L3MBTL1NPC1 | |
| SCHEMBL5739515 | 0.80 | MEN1 (0.45) | METAP1FFAR1L3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4028514 | 0.80 | CYP1A2 (0.43) | METAP1KDM4EFFAR1L3MBTL1NPC1 | |
| SCHEMBL4022692 | 0.80 | CYP1A2 (0.43) | METAP1KDM4EFFAR1L3MBTL1NPC1 | |
| SCHEMBL27930092 | 0.80 | KDM4E (0.54) | METAP1TDP1KDM4EFFAR1CCR1 | |
| SCHEMBL4019514 | 0.79 | NPC1 (0.44) | KDM4EGRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| EP-2903436-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014047257-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047257-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-1504001-B1 | 2-(2-PYRIDYL)-5-PHENYL-6-AMINOPYRIMIDINE, METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND USE THEREOF FOR COMBATING NOXIOUS FUNGI | BASF SE (DE) | 2009-04-15 | — | — | EP | disclosed |
| US-7320975-B2 | 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20050107401-A1 | 2- (2-pyridyl) -5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | METAP1 1803/4885TDP1 34/4885KDM4E 2439/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | METAP1 3017/4885TDP1 62/4885KDM4E 3159/4885 |
| US-20050107401-A1 | 2- (2-pyridyl) -5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi | HAAO, HAO1, DAO | METAP1 475/4885TDP1 377/4885KDM4E 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.